Amy Shapiro

List of Publications by Year
in descending order

22 papers	1,851 citations	516215 16 h-index	676716 22 g-index
22 all docs	22 docs citations	22 times ranked	999 citing authors

#	Article	IF	Citations
1	The effect of emicizumab prophylaxis on longâ€term, selfâ€reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies. Haemophilia, 2021, 27, 854-865.	1.0	21
2	Final results of the PUPs B-LONG study: evaluating safety and efficacy of rFIXFc in previously untreated patients with hemophilia B. Blood Advances, 2021, 5, 2732-2739.	2.5	11
3	The use of prophylaxis in the treatment of rare bleeding disorders. Thrombosis Research, 2020, 196, 590-602.	0.8	23
4	Realâ€world data demonstrate improved bleed control and extended dosing intervals for patients with haemophilia B after switching to recombinant factor IX Fc fusion protein (rFIXFc) for up to 5Âyears. Haemophilia, 2020, 26, 975-983.	1.0	12
5	Longâ€term safety and sustained efficacy for up to 5Âyears of treatment with recombinant factor IX Fc fusion protein in subjects with haemophilia B: Results from the Bâ€YOND extension study. Haemophilia, 2020, 26, e262-e271.	1.0	28
6	Young adult outcomes of childhood prophylaxis for severe hemophilia A: results of the Joint Outcome Continuation Study. Blood Advances, 2020, 4, 2451-2459.	2.5	67
7	Hemophilia A with inhibitor: Immune tolerance induction (ITI) in the mirror of time. Transfusion and Apheresis Science, 2019, 58, 578-589.	0.5	17
8	Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review. Research and Practice in Thrombosis and Haemostasis, 2019, 3, 528-541.	1.0	18
9	Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. Lancet Haematology,the, 2019, 6, e295-e305.	2.2	252
10	BIVV001: The First Investigational Factor VIII Therapy to Break Through the VWF Ceiling in Hemophilia A, with Potential for Extended Protection for One Week or Longer. Blood, 2018, 132, 636-636.	0.6	11
11	Plasma-derived human factor X concentrate for on-demand and perioperative treatment in factor X-deficient patients: pharmacology, pharmacokinetics, efficacy, and safety. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 97-104.	1.5	25
12	Safety and efficacy of recombinant factor VIIa by pediatric age cohort: reassessment of compassionate use and trial data supporting US label. Pediatric Blood and Cancer, 2016, 63, 1822-1828.	0.8	8
13	Switching to recombinant factor <scp>IX</scp> Fc fusion protein prophylaxis results in fewer infusions, decreased factor <scp>IX</scp> consumption and lower bleeding rates. British Journal of Haematology, 2015, 168, 113-123.	1.2	31
14	Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood, 2014, 123, 317-325.	0.6	403
15	Development of long-acting recombinant FVIII and FIX Fc fusion proteins for the management of hemophilia. Expert Opinion on Biological Therapy, 2013, 13, 1287-1297.	1.4	33
16	Association Of Bleeding Tendency With Time Under Target FIX Activity Levels In Severe Hemophilia B Patients Treated With Recombinant Factor IX Fc Fusion Protein. Blood, 2013, 122, 2349-2349.	0.6	9
17	Integrated analysis of safety and efficacy of a plasma- and albumin-free recombinant factor VIII (rAHF-PFM) from six clinical studies in patients with hemophilia A. Expert Opinion on Biological Therapy, 2009, 9, 273-283.	1.4	31
18	Surgical evaluation of a recombinant factor VIII prepared using a plasma/albumin-free method: Efficacy and safety of Advate in previously treated patients. Thrombosis and Haemostasis, 2008, 100, 217-223.	1.8	60

#	Article	IF	Citations
19	Home Treatment of Mild to Moderate Bleeding Episodes Using Recombinant Factor VIIa (Novoseven) in Haemophiliacs with Inhibitors. Thrombosis and Haemostasis, 1998, 80, 912-918.	1.8	350
20	Prospective, Randomised Trial of Two Doses of rFVIIa (NovoSeven) in Haemophilia Patients with Inhibitors Undergoing Surgery. Thrombosis and Haemostasis, 1998, 80, 773-778.	1.8	365
21	The pattern of spontaneous germ-line mutation: relative rates of mutation at or near CpG dinucleotides in the factor IX gene. Human Genetics, 1993, 91, 496-503.	1.8	42
22	A past mutation at Isoleucine397is now a common cause of moderate/mild haemophilia B. British Journal of Haematology, 1990, 75, 212-216.	1.2	34